# US 2022/0089597 A1 · Compounds and compositions for inhbiting the activity of shp2

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0089597 A1
- Document ID: US20220089597A1
- Status: Published application
- Kind: A1
- Application number: 17/191,082
- Filed: 2021-03-03
- Published: 2022-03-24
- Earliest claimed: 2015-06-19
- Assignees: Novartis AG
- Applicants: Novartis AG
- Inventors: Jeffrey T. Bagdanoff; Zhuoliang Chen; Michael Dore; Jorge Garcia Fortanet; Mitsunori Kato; Matthew J. LaMarche; Patrick James Sarver; Michael Shultz; Troy Douglas Smith; Sarah Williams
- Web page: https://patentgrep.com/patent/US20220089597A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61K 31/4523: containing further heterocyclic ring systems
- A61P 35/00: Antineoplastic agents
- C07D 471/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compounds of formula I: in which Y1, Y2, Y3, Y4 R1, R2, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

## Claims

### Claim 1

A compound, or a pharmaceutically acceptable salt thereof, of formula II:
in which:
Y5 is selected from N and CH;
Y6 is selected from CH2 and NH;
R1 is selected from R1a and —SR1a; wherein R1a is selected from phenyl, pyridinyl, pyrazinyl, pyridazinyl and pyrimidinyl; wherein said phenyl, pyridinyl, pyrazinyl, pyridazinyl or pyrimidinyl is unsubstituted or substituted with 1 to 3 R4 groups; wherein each R4 group is independently selected from halo, amino, morpholino, pyrrolidinyl, hydroxyl, C1-3alkyl, C1-3alkoxy and halo-substituted-C1-3alkyl;
R4a and R4b are each independently selected from hydrogen, hydroxy and fluoro; with proviso that R4a and R4b cannot both be OH;
R5a is selected from amino and amino-methyl;
R5b is selected from C1-6alkyl, methoxy-carbonyl, C3-6cycloalkyl-C1-3alkyl, hydroxy-substituted C1-3alkyl, C1-2alkoxy-substituted C1-3alkyl and a 5 to 6 member heteroaryl ring containing 1 to 4 heteroatoms selected from O, S and N; wherein said C1-6alkyl or C1-2alkoxy-substituted C1-3alkyl of R5b is unsubstituted or substituted with 1-3 fluorines; or R5a and R5b, together with the carbon atom to which R5a and R5b are attached, form a group selected from:
wherein *C represents the carbon atom to which R5a and R5b are attached; R10 is amino; R11a is selected from hydrogen, hydroxy, fluoro, C1-2alkyl and hydroxy-methyl; R11b is selected from fluoro, methyl and hydrogen; R11c is selected from hydrogen, C1-2alkyl and hydroxy-methyl; R12 is selected from hydrogen, halo, hydroxy, C1-3alkyl, halo-substituted-C1-3alkyl, halo-substituted-C1-3alkoxy and C1-3alkoxy; and R13 is selected from hydrogen, halo and C1-2alkyl; and
R6a and R6b are each independently selected from hydrogen, hydroxy and fluoro; with proviso that R6a and R6b cannot both be OH.

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, selected from:

### Claim 3 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

### Claim 4 (depends on 1)

A method of treatment comprising administering a compound of claim 1, or a pharmaceutically acceptable salt thereof, to a person in need of such treatment in an effective amount for the prophylactic or therapeutic treatment of a disease or disorder which is mediated by the activity of SHP2.

### Claim 5 (depends on 4)

The method of claim 4, wherein the disease or disorder mediated by the activity of SHP2 is selected from Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia, breast cancer, esophageal cancer, lung cancer, colon cancer, head cancer, neuroblastoma, squamous-cell carcinoma of the head and neck, gastric carcinoma, anaplastic large-cell lymphoma and glioblastoma.

### Claim 6

A compound, or a pharmaceutically acceptable salt thereof, which is:
